X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Webinar Summary: Need accurate isoform-level characterization? Iso-Seq is the answer

Thursday, November 14, 2019

Traditional RNA-Seq is done by fragmenting cDNA, and then sequencing the fragmented reads with paired-end sequencing. The problem comes when trying to identify the full-length isoform during assembly. This is computationally challenging, and sometimes intractable. 

Iso-Seq is a method of full-length transcript sequencing that eliminates the need for assembly

The solution? Long-read isoform sequencing, according to PacBio Principal Scientist Elizabeth Tseng and PacBio user Gloria Sheynkman, a research fellow at Dana-Farber Cancer Institute. The two recently participated in a webinar, sharing their experiences using PacBio’s Iso-Seq method.

Tseng started by explaining the method and some of its applications. 

“In contrast to traditional RNA-Seq, the Iso-Seq method produces full-length cDNA, and using the PacBio long, accurate reads, can sequence the full transcript. No assembly is required,” Tseng said.

She also discussed some of the bioinformatics tools available, including SQANTI2, which can be used to classify full-length transcripts against annotations such as GENCODE, and as a quality control tool. 

 

The Iso-Seq method in action

At Dana Farber, Sheynkman uses the Iso-Seq method to characterize cancer cells and create complete, accurate transcriptomes. 

In one example, she ran five breast cancer cell lines and eight melanoma samples in one pooled library on a single SMRT Cell 8M each, achieving around 6 million polymerase reads, with an average base yield of 300 Gb and an average polymerase read length of ~50 kb. Sequencing was performed by Maryland Genomics, a PacBio certified service provider.

With the improvements in the chemistry of the new Sequel II System, Sheynkman said she has been able to capture a much wider range of transcript lengths, without having to do size selection.

“Overall, we’re really detecting a much larger range, with cDNA molecules up to 6 and 7 kb,” she said.

For both breast cancer and melanoma, she obtained about 14,000 unique genes and 11,000 unique isoforms, around 30% of which were novel. And each SMRT Link Iso-Seq job was completed in just 6-9 hours, she noted.

 

Towards accurate isoform quantification

Gloria Sheynkman, Research fellow at Dana-Farber Cancer Institut

But the most promising application for Sheynkman is isoform quantification.

“I think this is a really important goal for the field,” she said. “To know how many copies of each transcript is expressed in the cell will really open up a lot of avenues in biomedical research, such as having consistent biomarkers, understanding disease mechanisms, and even just fundamental biological understanding.”

While short-read sequencing can achieve gene quantification with reliable results, the complexity of isoform structure requires more comprehensive coverage. 

“Isoform quantification methods are very dependent on having accurate transcript models,” Sheynkman said.

The improved depth of coverage and reduced bias in sampling full-length reads on the new Sequel II System should mitigate these limitations, Sheynkman said. And the high technical reproducibility achieved by PacBio is another big strength, she added. 

 

Targeted or whole transcriptome sequencing?

Sheynkman further discussed cases in which targeted isoform sequencing may be preferred over whole transcriptome sequencing. By targeting only genes of interest, rare isoforms could be identified with low to moderate sequencing effort. Multiplexing could further reduce the cost and increase sample size, which could be useful for applications such as biomarker discovery and validation.

Sheynkman also provided a new solution to a common problem when doing targeted sequencing: probes. ORF Capture-Seq is designed as an easy, versatile option to make capture probes directly from available clones/PCR product within a single day, using low-cost molecular biology reagents. It also allows for the generation of many complex probe sets tailored to different genes, Sheynkman said. The complexity of the probe sets allows you to target anywhere from 1 to 1,000 genes. 

 

ORF Capture-Seq enables capture probes to be made directly from available clones/PCR products using low-cost molecular biology reagents

 

The webinar also included a lively Q&A that is well worth the listen.

 

Subscribe for blog updates:

Archives